***In April, a Trump-appointed federal judge suspended approval of the drug, which is used in more than half of all abortions nationwide. The 5th U.S. Circuit Court of Appeals later ruled the pill, which was approved by the FDA in 2000, could remain on the market, but the panel upheld portions of the earlier decision, rolling back changes the FDA made since 2016, which eased access.
The 5th Circuit ruled the FDA acted improperly when it said mifepristone can be used up to 10 weeks of pregnancy rather than seven, allowed the medication to be mailed to patients, lowered the dosage and permitted providers other than physicians to prescribe the drug.
Now, the justices are scheduled to consider petitions to review that ruling from the Biden administration and Danco Laboratories, which manufactures the brand-name version of mifepristone.
No comments:
Post a Comment